Synapse - Works

Results (76)

Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed/refractory multiple myeloma (RRMM): Updated results from an ongoing phase I study

Meeting Abstract

Trudel, S.; Cohen, A. D.; Krishnan, A. Y.; Fonseca, R.; Spencer, A.; Berdeja, J. G.; Lesokhin, A.; Forsberg, P. A.; Laubach, J. P.; Costa, L. J.; more...
Blood (2021)

Fulltext@MSK | Save

Prevalence of smoldering multiple myeloma: Results from the Iceland screens, treats, or prevents multiple myeloma (iStopMM) study

Meeting Abstract

Thorsteinsdottir, S.; Gislason, G. K.; Aspelund, T.; Rögnvaldsson, S.; Oskarsson, J. T. T.; Petirsdottir, I.; Sigurdsson, J. K.; Sigurdardottir, G. A.; Thordardottir, A. R.; Vidarsson, B.; more...
Blood (2021)

Fulltext@MSK | Save

Estimating selection bias in previous monoclonal gammopathy of undetermined significance research - the importance of screening: Results from the population-based screening study Iceland screens, treats or prevents multiple myeloma (iStopMM)

Meeting Abstract

Sigurbergsdóttir, A. Ý.; Rögnvaldsson, S.; Thorsteinsdottir, S.; Sverrisdottir, I. S.; Sigurdardottir, G. A.; Vidarsson, B.; Onundarson, P. T.; Agnarsson, B. A.; Sigurdardottir, M.; Thorsteinsdottir, I.; more...
Blood (2021)

Fulltext@MSK | Save

Daratumumab versus lenalidomide maintenance therapy for multiple myeloma: A randomized pilot study comparing patient-reported health related quality of life measures

Meeting Abstract

Shah, U. A.; Malik, M.; Werner, K.; Burge, M.; Devlin, S. M.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Tan, C.; more...
Blood (2021)

Fulltext@MSK | Save

A pilot plant-based dietary intervention in overweight and obese patients with monoclonal gammopathy of undetermined significance and smoldering multiple myeloma- the Nutrition Prevention (NUTRIVENTION) study

Meeting Abstract

Shah, U. A.; Alicea, D.; Adintori, P. A.; Burge, M.; Blaslov, J.; Derkach, A.; Mailankody, S.; Korde, N.; Tan, C.; Hultcrantz, M.; more...
Blood (2021)

Fulltext@MSK | Save

Elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: Results from MagnetisMM-1

Meeting Abstract

Sebag, M.; Raje, N. S.; Bahlis, N. J.; Costello, C.; Dholaria, B.; Solh, M.; Levy, M. Y.; Tomasson, M. H.; Dube, H.; Damore, M. A.; more...
Blood (2021)

Fulltext@MSK | Save

Monoclonal gammopathy of undetermined significance and COVID-19: Results from the population-based Iceland screens treats or prevents multiple myeloma study (iStopMM)

Meeting Abstract

Rögnvaldsson, S; Eythorsson, E.; Thorsteinsdottir, S.; Vidarsson, B.; Onudarson, P. T.; Agnarsson, B. A.; Sigurdardottir, M.; Horsteinsdottir, I.; Olafsson, I.; Runolfsdottir, H. L.; more...
Blood (2021)

Fulltext@MSK | Save

CD47-blocker TTI-622 shows single-agent activity in patients with advanced relapsed or refractory lymphoma: Update from the ongoing first-in-human dose escalation study

Meeting Abstract

Patel, K.; Zonder, J. A.; Sano, D.; Maris, M.; Lesokhin, A.; von Keudell, G.; Lai, C.; Ramchandren, R.; Catalano, T.; Lin, G. H. Y.; more...
Blood (2021)

Fulltext@MSK | Save

Genomic and immune signatures predict sustained MRD negativity in newly diagnosed multiple myeloma patients treated with daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd)

Meeting Abstract

Maura, F.; Boyle, E. M.; Diamond, B.; Blaney, P.; Ghamlouch, H.; Ziccheddu, B.; Wang, Y.; Maclachlan, K. H.; Hoffman, J. E.; Hassoun, H.; more...
Blood (2021)

Fulltext@MSK | Save

Universal updated phase 1 data validates the feasibility of allogeneic anti-BCMA ALLO-715 therapy for relapsed/refractory multiple myeloma

Meeting Abstract

Mailankody, S.; Liedtke, M.; Sidana, S.; Matous, J. V.; Chhabra, S.; Oluwole, O. O.; Malik, S. A.; Kumar, S.; Nath, R.; Anwer, F.; more...
Blood (2021)

Fulltext@MSK | Save